This is a working overview of Preclinical research, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-11 and is reviewed periodically as new material appears.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Visual description for typical solid reference material. |
| Solubility | Poorly soluble in water; soluble in DMSO | Solubility depends on solvent, purity, and form. |
| Storage | Cool, dry, protected from light | Long-term storage often uses low temperature and desiccant. |
| Common analytical method | LC-MS/MS | Used for detection and quantification in biological matrices. |
| Common synonyms | GW-501516; GW501516; endurobol | Naming varies among literature, vendors, and databases. |
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Australia has adopted a number of strategies to combat money laundering, which mirror those of a majority of western countries. The Australian Transaction Reports and Analysis Centre (AUSTRAC) is Australia's financial intelligence unit to combat money laundering and terrorism financing, which requires every provider of designated services in Australia to report to it suspicious cash or other transactions and other specific information. The Attorney-General's Department maintains a list of outlawed terror organisations. It is an offense to materially support or be supported by such organisations. It is an offence to open a bank account in Australia in a false name, and rigorous procedures must be followed when new bank accounts are opened. The Anti–Money Laundering and Counter–Terrorism Financing Act 2006 (Cth) (AML/CTF Act) is the principal legislative instrument, although there are also offence provisions contained in Division 400 of the Criminal Code Act 1995 (Cth). Upon its introduction, it was intended that the AML/CTF Act would be further amended by a second tranche of reforms extending to designated non-financial businesses and professions (DNFBPs) including, inter alia, lawyers, accountants, jewellers and real estate agents; however, those further reforms have yet to be progressed. The Proceeds of Crime Act 2002 (Cth) imposes criminal penalties on a person who engages in money laundering.
== Effects and symptoms == Hemoglobin in combination with normal hemoglobin (heterozygous HBD/HbA) is asymptomatic, causing no effects. Individuals have normal hemoglobin level and their red blood cells are normal spherical structure. Homozygous HbD/HbD causes mild hemolytic anemia and chronic non-progressive splenomegaly (enlargement of spleen). Heterozygous HbD/HbS causes sickle cell anemia. However, most cases of the disease are milder than the usual HbS/HbS conditions. The most serious complication noted is stroke. HbD-thalassemia causes microcytic anemia which is generally milder that in typical thalassemia.
=== Mechanism of action === Elexacaftor/tezacaftor/ivacaftor is a tridrug treatment in which the medications work together to increase the transport of chloride and sodium ions and correct fluid shifts that are dysregulated in cystic fibrosis. Its effectiveness is dependent on the type of CF mutations the patient has.
On 26 July, a mortar strike from Afghanistan on Zamchan in South Waziristan killed a woman and imjured two children. A TTP militant was killed in a skirmish in Regi Model town of Peshawar while two dead bodies of TTP militants were recovered from Bannu District. Militants attacked the Gandak border post of the 133 Wing of the SWS Brigade in Azam Warsak area of South Waziristan killing three FC soldiers. Two civilians were injured in a militant drone strike on Hadi village of Mirali. Two soldiers were killed and one was wounded in an IED attack in Spinwam. On 27 July, a quadcopter strike on a mosque in Birmal Tehsil killed a cleric and wounded two. A joint counterterrorism operation was started in the border hill tracts of Abdul Khel, Shah Hassan Khel, and Hayat Khel area of Lakki Marwat District forcing insurgents to flee while a senior TTP commander was also killed in the Wanda Semo area. An off-duty FC soldier was killed in the Dildar Garhi area of Charsadda District. On 28 July, a counter-terrorism operation was launched in the Shalkho Sar area of Swat following the abduction of a Village defense guard while four TTP militants and one Special Operations Team personnel were killed in an operation in the Matta area of Swat District. Insurgents blew up a mosque in the Lachi area of Kohat District. The operation continued in Lakki Marwat with two alleged underground militant bunker and equipment being destroyed. Three soldiers were killed and four wounded in a TTP ambush in the Shoi Khel area of Shawal tehsil.
While Miller stated that male scientists such as Stephen Jay Gould and Donald Symons "have viewed the female clitoral orgasm as an evolutionary side-effect of the male capacity for penile orgasm" and that they "suggested that clitoral orgasm cannot be an adaptation because it is too hard to achieve", Gould acknowledged that "most female orgasms emanate from a clitoral, rather than vaginal (or some other), site" and that his nonadaptive belief "has been widely misunderstood as a denial of either the adaptive value of female orgasm in general or even as a claim that female orgasms lack significance in some broader sense". He said that although he accepts that "clitoral orgasm plays a pleasurable and central role in female sexuality and its joys", "[a]ll these favorable attributes, however, emerge just as clearly and just as easily, whether the clitoral site of orgasm arose as a spandrel or an adaptation". He added that the "male biologists who fretted over [the adaptionist questions] simply assumed that a deeply vaginal site, nearer the region of fertilization, would offer greater selective benefit" due to their Darwinian, summum bonum beliefs about enhanced reproductive success. Similar to Gould's beliefs about adaptionist views and that "females grow nipples as adaptations for suckling, and males grow smaller unused nipples as a spandrel based upon the value of single development channels", American philosopher Elisabeth Lloyd suggested that there is little evidence to support an adaptionist account of female orgasm. Canadian sexologist Meredith L.
Sources: en.wikipedia.org
==== Electron-capture dissociation ==== If an electron is added to a multiply charged positive ion, the Coulomb energy is liberated. Adding a free electron is called electron-capture dissociation (ECD), and is represented by
In situ leaching or in situ recovery refers to the mining technique of injecting lixiviant underground to dissolve ore and bringing the pregnant leach solution to surface for extraction. Commonly used in uranium mining but has also been used for copper mining.
Recently VESA has experienced quite a few complaints regarding troublesome DisplayPort operation that ended up being caused by improperly made DisplayPort cables. These "bad" DisplayPort cables are generally limited to non-DisplayPort certified cables, or off-brand cables. To further investigate this trend in the DisplayPort cable market, VESA purchased a number of non-certified, off-brand cables and found that an alarmingly high number of these were configured improperly and would likely not support all system configurations. None of these cables would have passed the DisplayPort certification test, moreover some of these cables could potentially damage a PC, laptop, or monitor.
== Selected articles == Meyer, D. E., & Chilkoti, A. (1999). Purification of recombinant proteins by fusion with thermally-responsive polypeptides. Nature Biotechnology, 17(11), 1112–1115. Nath, N., & Chilkoti, A. (2002). A colorimetric gold nanoparticle sensor to interrogate biomolecular interactions in real time on a surface. Analytical chemistry, 74(3), 504–509. Ma, H., Hyun, J. Chilkoti, A. (2004). "Nonfouling" oligoethylene glycol functionalized polymer brushes synthesized by surface-initiated atom transfer radical polymerization. Advanced Materials, 16, 338–341. Dreher, M. R., Liu, W., Michelich, C. R., Dewhirst, M. W., Yuan, F., & Chilkoti, A. (2006). Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. Journal of the National Cancer Institute, 98(5), 335–344. Ciracì, C., Hill, R. T., Mock, J. J., Urzhumov, Y., Fernández-Domínguez, A. I., Maier, S. A., ... & Smith, D. R. (2012). Probing the ultimate limits of plasmonic enhancement. Science, 337(6098), 1072–1074.
Sources: en.wikipedia.org
=== EC 1.5.1 With NAD+ or NADP+ as acceptor === EC 1.5.1.1: 1-piperideine-2-carboxylate/1-pyrroline-2-carboxylate reductase (NAD(P)H) EC 1.5.1.2: pyrroline-5-carboxylate reductase EC 1.5.1.3: dihydrofolate reductase EC 1.5.1.4: Now included with EC 1.5.1.3 dihydrofolate reductase EC 1.5.1.5: methylenetetrahydrofolate dehydrogenase (NADP+) EC 1.5.1.6: formyltetrahydrofolate dehydrogenase EC 1.5.1.7: saccharopine dehydrogenase (NAD+, L-lysine-forming) EC 1.5.1.8: saccharopine dehydrogenase (NADP+, L-lysine-forming) EC 1.5.1.9: saccharopine dehydrogenase (NAD+, L-glutamate-forming) EC 1.5.1.10: saccharopine dehydrogenase (NADP+, L-glutamate-forming) EC 1.5.1.11: D-octopine dehydrogenase EC 1.5.1.12: Now EC 1.2.1.88, L-glutamate γ-semialdehyde dehydrogenase EC 1.5.1.13: Now EC 1.17.1.5, nicotinate dehydrogenase EC 1.5.1.14: Now included with EC 1.5.1.21 Δ1-piperideine-2-carboxylate reductase EC 1.5.1.15: methylenetetrahydrofolate dehydrogenase (NAD+) EC 1.5.1.16: D-lysopine dehydrogenase EC 1.5.1.17: alanopine dehydrogenase EC 1.5.1.18: ephedrine dehydrogenase EC 1.5.1.19: D-nopaline dehydrogenase EC 1.5.1.20: methylenetetrahydrofolate reductase (NAD(P)H) EC 1.5.1.21: 1-piperideine-2-carboxylate/1-pyrroline-2-carboxylate reductase (NADPH) EC 1.5.1.22: strombine dehydrogenase EC 1.5.1.23: tauropine dehydrogenase EC 1.5.1.24: N5-(carboxyethyl)ornithine synthase EC 1.5.1.25: thiomorpholine-carboxylate dehydrogenase EC 1.5.1.26: β-alanopine dehydrogenase EC 1.5.1.27: 1,2-dehydroreticulinium reductase (NADPH) EC 1.5.1.28: opine dehydrogenase EC 1.5.1.29: Now covered by EC 1.5.1.38 [FMN reductase (NADPH)], EC 1.5.1.39 [FMN reductase [NAD(P)H])] and EC 1.5.1.41 (riboflavin reductase [NAD(P)H]) EC 1.5.1.30: flavin reductase (NADPH) EC 1.5.1.31: berberine reductase EC 1.5.1.32: vomilenine reductase EC 1.5.1.33: pteridine reductase EC 1.5.1.34: 6,7-dihydropteridine reductase EC 1.5.1.35: identical to EC 1.2.1.19, aminobutyraldehyde dehydrogenase, as the substrates 1-pyrroline and 4-aminobutanal are interconvertible EC 1.5.1.36: flavin reductase (NADH) EC 1.5.1.37: FAD reductase (NADH) EC 1.5.1.38: FMN reductase (NADPH) EC 1.5.1.39: FMN reductase (NAD(P)H) EC 1.5.1.40: 8-hydroxy-5-deazaflavin:NADPH oxidoreductase EC 1.5.1.41: riboflavin reductase (NAD(P)H) EC 1.5.1.42: FMN reductase (NADH) EC 1.5.1.43: carboxynorspermidine synthase EC 1.5.1.44: festuclavine dehydrogenase EC 1.5.1.45: FAD reductase (NAD(P)H) EC 1.5.1.46: agroclavine dehydrogenase EC 1.5.1.47: dihydromethanopterin reductase [NAD(P)+] EC 1.5.1.48: 2-methyl-1-pyrroline reductase EC 1.5.1.49: 1-pyrroline-2-carboxylate reductase [NAD(P)H] EC 1.5.1.50: dihydromonapterin reductase EC 1.5.1.51: N-[(2S)-2-amino-2-carboxyethyl]-L-lutamate dehydrogenase EC 1.5.1.52: staphylopine dehydrogenase EC 1.5.1.53: methylenetetrahydrofolate reductase (NADPH) EC 1.5.1.54: methylenetetrahydrofolate reductase (NADH)
Other reagents present in amounts greater than required to react with all the limiting reagent present are considered excess. As a result, the yield should not be automatically taken as a measure for reaction efficiency. In their 1992 publication General Chemistry, Whitten, Gailey, and Davis described the theoretical yield as the amount predicted by a stoichiometric calculation based on the number of moles of all reactants present. This calculation assumes that only one reaction occurs and that the limiting reactant reacts completely. According to Whitten, the actual yield is always smaller (the percent yield is less than 100%), often very much so, for several reasons. As a result, many reactions are incomplete and the reactants are not completely converted to products. If a reverse reaction occurs, the final state contains both reactants and products in a state of chemical equilibrium. Two or more reactions may occur simultaneously, so that some reactant is converted to undesired side products. Losses occur in the separation and purification of the desired product from the reaction mixture. Impurities are present in the starting material which do not react to give desired product.
Aleniglipron (development code GSBR-1290) is a small-molecule GLP-1 agonist developed by Structure Therapeutics. It is delivered orally and is in a Phase II trial as of 2023. In June 2024, Structure Therapeutics reported positive topline data from a Phase 2a obesity study in which GSBR-1290 demonstrated clinically meaningful and statistically significant placebo-adjusted mean weight loss and generally favorable safety and tolerability results.
=== Centering the Z-Ring === One model of Z-ring formation permits its formation only after a certain spatial signal that tells the cell that it is big enough to divide. The MinCDE system prevents FtsZ polymerization near certain parts of the plasma membrane. MinD localizes to the membrane only at cell poles and contains an ATPase and an ATP-binding domain. MinD is only able to bind to the membrane when in its ATP-bound conformation. Once anchored, the protein polymerizes, resulting in clusters of MinD. These clusters bind and then activate another protein called MinC, which has activity only when bound by MinD. MinC serves as a FtsZ inhibitor that prevents FtsZ polymerization. The high concentration of a FtsZ polymerization inhibitor at the poles prevents FtsZ from initiating division at anywhere but the mid-cell. MinE is involved in preventing the formation of MinCD complexes in the middle of the cell. MinE forms a ring near each cell pole. This ring is not like the Z-ring. Instead, it catalyzes the release of MinD from the membrane by activating MinD's ATPase. This hydrolyzes the MinD's bound ATP, preventing it from anchoring itself to the membrane. MinE prevents the MinD/C complex from forming in the center but allows it to stay at the poles. Once the MinD/C complex is released, MinC becomes inactivated. This prevents MinC from deactivating FtsZ. As a consequence, this activity imparts regional specificity to Min localization. Thus, FtsZ can form only in the center, where the concentration of the inhibitor MinC is minimal.
== Professional sphere == Women obtained the legal right to work without spousal authorization under the law of July 13, 1965, which came into effect on 1 February 1966. As of recent data (excluding Mayotte), 68.2% of women aged 15–64 were active in the labor market, compared to 75.8% of men in the same age group. According to a CFTC report, 49% of women reported that having a child significantly affected their employment situation, compared to 14% of men. These effects may include job changes, reductions in working hours, or parental leave.
Sources: en.wikipedia.org
Cardarine targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not bind the androgen receptor in the way SARMs do.
Most methods use liquid chromatography with tandem mass spectrometry. Urine is common in anti-doping testing, and blood or plasma may be used in research.
Typical guidance is cool, dry, dark storage, often at low temperature and with desiccant. Stability data are limited, so storage conditions should be verified for each batch or supplier.
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.